Pertuzumab: observed
44 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.
- Clinical and Therapeutic Outcomes by Molecular Subtype in Breast CancerRecruitingNCT07856225Report a problem
- Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic DiseaseRecruitingNCT07542496Report a problem
- A Real-World Study on the Impact of Different Adjuvant Treatment Regimens on Prognosis in Non-pCR Patients With HER2-Positive Breast Cancer After Neoadjuvant TherapyNot yet recruitingNCT07540520Report a problem
- Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast CancerNot yet recruitingNCT07470203Report a problem
- Efficacy of Neoadjuvant Subcutaneous Trastuzumab-Pertuzumab in Algerian Women With Locally Advanced HER2 Positive Breast CancerRecruitingNCT07166185Report a problem
- Concomitant Radiotherapy and New Drugs in Metastatic Breast CancerRecruitingNCT07021911Report a problem
- Emotional Distress in Patients With Metastatic Breast Cancer in First Line of TherapyRecruitingNCT06994377Report a problem
- Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast CancerRecruitingNCT06722612Report a problem
- Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive PatientsRecruitingNCT06722599Report a problem
- Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target TherapyRecruitingNCT06711068Report a problem
- De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive PatientsRecruitingNCT06700369Report a problem
- Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant TherapyRecruitingNCT06693037Report a problem
- Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast CancerRecruitingNCT05912062Report a problem
- Neoadjuvant Treatment of Breast CancerNot yet recruitingNCT05131893Report a problem
- Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical StudyNot yet recruitingNCT04831528Report a problem
- Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast CancerRecruitingNCT04638725Report a problem
- First-Line Dual Versus Single HER2-Targeted Therapy With Docetaxel for Advanced HER2-Positive Breast CancerCompletedNCT07829900Report a problem
- Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast CancerCompletedNCT07416409Report a problem
- Extracellular Fluid Changes During Neoadjuvant ChemotherapyCompletedNCT07315880Report a problem
- Sarcopenia and Paclitaxel-Induced Neuropathy in Early Stage Breast Cancer (Neuro-Sarc)CompletedNCT06996548Report a problem
- An Observational, Multicenter Study Evaluating the Safety of ReAl-lifePertuzumab and Trastuzumab Fixed Dose Combination: the RAPID StudyCompletedNCT06835348Report a problem
- Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 TreatmentActive, not recruitingNCT06663787Report a problem
- RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal AntibodyActive, not recruitingNCT06481553Report a problem
- Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus TrastuzumabCompletedNCT05572645Report a problem
- KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors IIActive, not recruitingNCT05525858Report a problem
- Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With TrastuzumabStatus unknownNCT05188495Report a problem
- a Prospective Registration Study for Patients With Advanced Refractory Solid TumorsStatus unknownNCT05177666Report a problem
- Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 TreatmentStatus unknownNCT04769050Report a problem
- The Efficacy and Safety of Neoadjuvant Trastuzumab Plus Taxane With and Without Pertuzumab TherapyStatus unknownNCT04765124Report a problem
- Efficacy and Safety of Eribulin in the Treatment of Advanced Breast CancerStatus unknownNCT04683445Report a problem
- PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter StudyStatus unknownNCT04644406Report a problem
- An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 PandemicApproved for marketingNCT04395508Report a problem
- A Study to Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted TherapiesStatus unknownNCT04288141Report a problem
- Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP ChemotherapyStatus unknownNCT04276337Report a problem
- A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin AmericaCompletedNCT04158258Report a problem
- Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast CancerStatus unknownNCT03979911Report a problem
- CARdiac Function Evaluation in Breast Cancer PatientsCompletedNCT03266809Report a problem
- Outcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab EmtansineCompletedNCT03025711Report a problem
- Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer PatientsStatus unknownNCT02642458Report a problem
- Observational Study of Pertuzumab Safety in Participants With Breast CancerCompletedNCT02266173Report a problem
- Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and TaxanesStatus unknownNCT02101879Report a problem
- NSABP Biospecimen Discovery ProjectStatus unknownNCT01850628Report a problem
- HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin TherapyCompletedNCT01777958Report a problem
- A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab EmtansineCompletedNCT00833963Report a problem